Join to access to all OVN content. Join for Free
MSL Visibility - How to SUCCEED in 2024
Medical Science Liaisons MSL effectiveness MSL visibility MSL strategies Eleonora Goldberg

MSL Visibility - How to SUCCEED in 2024


Share This Article


Summary

Tom Caravela welcomes Eleonora Goldberg to explore the evolving role of Medical Science Liaisons (MSLs) within organizations. They delve into the key attributes leaders seek in MSLs and share strategies for standing out and enhancing team performance. Essential skills for MSL effectiveness and methods for evaluating performance are discussed, alongside preparing for industry changes and maintaining positivity in 2024. Eleonora offers predictions and expresses optimism for the future of MSLs. The episode concludes with closing remarks, appreciation, and a reminder to subscribe and stay engaged.

My guest this week is Eleonora Goldberg, Vice President, Medical Affairs at Arrowhead Pharmaceuticals and we discuss MSL Visibility and how to succeed in 2024.

 Eleonora shares….

πŸ‘‰ What is the VALUE of MSLs
πŸ‘‰ What leaders look for in MSLs
πŸ‘‰ How can MSLs separate themselves from their peers
πŸ‘‰ How might 2024 be different for MSLs
πŸ‘‰ What advice is there for dealing with uncertainty

Click for Source
Medical Science Liaisons, MSL effectiveness, MSL visibility, MSL strategies, Eleonora Goldberg

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN